Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer

Journal of the National Cancer Institute

Volumn 88, Issue 8, 1996, Pages 536-541

  Kundu, Namita ^a   Beaty, Theresa L ^a   Jackson, Marian J ^a   Fulton, Amy M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SIZE; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; CRICETINAE; FEMALE; HUMANS; INTERLEUKIN-10; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, SCID; NEOPLASM METASTASIS; TUMOR CELLS, CULTURED;

EID: 0029875958     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.8.536     Document Type: Article

References (22)

1. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
2. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12.
3. Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumoi cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992;52:3679-86.
4. Brunda MJ, Luistro L, Warner RR. Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993, 178:1223-30.
5. Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992;13. 198-200.
6. Bogdan C, Nathan C. Modulation of macrophage function by transforming growth factor β, interleukin-4 and interleukin-10. Ann NY Acad Sci 1993;685:713-39.
7. Powrie F, Menon S, Coffman RL. Interleukin-4 and interleukin-10 synergize to inhibit cell mediated immunity in vivo. Eur J Immunol 1993;23:3043-9.
8. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, et al. A randomized, controlled trial of IL-10 in humans Inhibition of inflammatory cytokine production and immune response. J Immunol 1995, 154:5492-9.
9. Richter G, Kruger-Krasagakes S, Hein G, Huls C, Schmitt E, Diamantstein T, et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 1993;53:4134-7.
10. Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 1983;3:22-31.
11. Schwarz MA, Hamilton LD, Tardelli L, Narula SK, Sullivan SK. Stimulation of cytolytic activity by interleukin-10 J Immunother Emphasis Tumor Immunol 1994:16:95-104.
12. Carson WE, Lindemann MJ, Baiocchi R, Linett M, Tan JC, Chou CC, et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995;85:3577-85.
13. Fulton AM. Interactions of natural effector cells and prostaglandins in the control of metastasis. J Natl Cancer Inst 1987;78:735-41.
14. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, et al. Immunizing and curative potential of replicating and non-replicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res 1994;54: 6022-6.
15. Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 1995;155:3112-23
16. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170: 2081-95.
17. de Waal Malefyt R, Haanen J, Spits H, Roncarlo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-24.
18. Nishijima K, Hisatsune T, Minai Y, Kohyama M, Kaminogawa S. Anti-IL-10 antibody enhances the proliferation of CD8+ T cell clones: autoregulatory role of murine IL-10 in CD8+ T cells. Cell Immunol 1994;154:193-201.
19. Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to mterleukin-6 expression. Int J Cancer 1993;55:96-101.
20. Kurt RA, Park JA, Panelli MC, Schluter SF, Marchalonis JJ, Carolus B, et al. T lymphocytes infiltrating sites of tumor rejection and progression display identical Vβ usage but different cytotoxic activities. J Immunol 1995; 154:3969-74.
21. Chen WF, Zlotnik A IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147:528-34.
22. Jinquan T, Larsen CG, Gesser B, Matsushima K. Thestrup-Pedersen K. Human IL-10 is a chemoattractant for CD8+ T lymphocytes and an inhibitor of IL-8-induced CD4+ T lymphocyte migration. J Immunol 1993;151:4545-51.